PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBApproximately 300,000 patients in the US will be eligible for the therapy. Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront. J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study. Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis.
FDA approves updated COVID-19 vaccines to better protect …
WEBAug 23, 2024 · The US Food and Drug Administration (FDA) has approved updated COVID-19 vaccines from Pfizer/BioNTech and Moderna to better protect against currently circulating variants. The updated vaccines target the KP.2 strain, a descendant of the JN.1 variant that was circulating in the US earlier this year, …
Moderna shares positive phase 3 results for mRNA influenza …
WEBSep 15, 2023 · Moderna has shared positive results from a late-stage trial of its influenza vaccine, with mRNA-1010 shown to generate a stronger immune response against all four World Health Organization (WHO)-recommended flu strains compared to GSK’s Fluarix. Improved immunogenicity was observed across age …
FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 …
WEBSep 12, 2023 · The US Food and Drug Administration (FDA) has approved updated COVID-19 vaccines from Pfizer/BioNTech and Moderna to more closely target currently circulating variants.
PME - Home
WEBHow AI and digital innovations can help agencies and pharma support HCPs in the fight against COVID-19 - PME Supplement August 2020. As the realities of COVID-19 hit and lockdown restrictions came into force around the world, agencies and pharma suddenly found themselves embracing AI and digital innovations at an accelerated rate.
Pfizer and BioNTech share positive results for Omicron-adapted …
WEBJun 27, 2022 · Pfizer and BioNTech have shared positive results from a phase 2/3 trial of two Omicron-adapted COVID-19 vaccine candidates. The data shows that a booster dose of both Omicron-adapted vaccines gave a considerably higher immune response against Omicron BA.1, compared to Pfizer/BioNTech’s current COVID-19 vaccine.
PME - Articles - Pharmaceutical Market Europe
WEBSep 11, 2024 · News - July/Aug 2024. Roche and Ascidian agree to $1.8bn neurological disease partnership. 15 July 2024 News & Columns. Read More. Dermatology news - July/Aug 2024. UCB’s Bimzelx approved by MHRA for hidradenitis suppurativa. 15 July 2024 News & Columns. Read More. DARWIN'S MEDICINE - Bayer's octopus move.
COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
WEBSep 24, 2021 · After months of controversy, the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have given a green light to the COVID-19 booster programme in the US.
Expert review shows AstraZeneca’s COVID-19 vaccine is ‘equally ...
WEBJul 13, 2022 · The study informs policymakers about the optimal deployment of COVID-19 vaccines over the next 12 months. AstraZeneca’s (AZ) COVID-19 vaccine, Vaxzevria, and the available mRNA COVID-19 vaccines provide ‘equally effective’ protection against hospitalisation and death, an expert review of data from 79 real-world studies has revealed.
PME - Magazine Issues - Pharmaceutical Market Europe
WEBJun 11, 2024 · PME - Magazine Issues. Latest Oldest Title Title. Pharmaceutical Market Europe Jun 11, 2024. June 2024 - Pharmaceutical Market Europe. GSK’s Jack Harris on innovation in oncology; Harnessing creativity in a digital age; Sustainability in pharma. Subscribe. Pharmaceutical Market Europe May 15, 2024. May 2024 - Pharmaceutical Market Europe.